01—Abstract
Summary
Summary of the 8-K filed August 16, 2024. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company (LLY) disclosed in this Form 8-K, filed August 16, 2024, that director Dr. Marschall S.
Runge will retire from the Board of Directors effective August 31, 2024. Per the filing, his decision did not arise from any disagreement with the Company on its operations, policies or practices. The disclosure is a governance update under Item 5.02 and does not include financial results, guidance, or material financial statements; the only attached exhibit is the press release (Exhibit 99.1) and the XBRL cover page.
Runge has served on the board since 2013, sitting on the Science and Technology Committee and the Ethics and Compliance Committee. The press release notes that he is CEO of Michigan Medicine and dean of the University of Michigan Medical School, and that he plans to retire from those leadership roles on June 30, 2025, after which he will remain on the faculty. CEO David A.
Ricks thanked him for his service and his expertise in science and medical affairs. For investors, this is a routine board transition with limited direct financial impact.
The main considerations are the loss of a director with clinical trial, biomedical research, and diabetes/obesity expertise, and the Science and Technology and Ethics and Compliance committee seats that will need to be filled or reassigned. The filing does not name a successor or describe any compensation or other arrangements.
02—Key points
Key Highlights
- Dr. Marschall S. Runge, an independent director since 2013, will retire from Lilly's Board effective August 31, 2024.
- The filing states his retirement was not due to any disagreement with the Company on operations, policies or practices.
- Runge sat on the Science and Technology Committee and the Ethics and Compliance Committee.
- He is CEO of Michigan Medicine and dean of the University of Michigan Medical School, with plans to retire from those roles on June 30, 2025, and remain on the faculty.
- His background spans physician-scientist work, clinical trial design, patient safety, and principal investigator experience in diabetes and obesity treatments.
- No successor, board appointment, or compensation arrangement is disclosed in this filing.
- The filing contains no financial results, guidance, or financial statements; the only exhibit is the press release and XBRL cover page.
03—Questions
Frequently Asked Questions
Why is Dr. Runge leaving Lilly's Board?
The 8-K states that his decision to retire from the Board did not arise from any disagreement with the Company on operations, policies or practices. The press release describes his retirement as tied to his academic and health system responsibilities, not to any dispute with Lilly.
Does this announcement affect Lilly's financial results or guidance?
No. The filing is a governance disclosure under Item 5.02 and contains no financial results, guidance, or financial statements. Its direct financial impact is expected to be minimal.
Which board committees did Dr. Runge serve on, and what happens to those seats?
He served on the Science and Technology Committee and the Ethics and Compliance Committee. The filing does not say who will replace him or how the committee roles will be reassigned.
What expertise does Dr. Runge bring that Lilly will lose?
According to the press release, he brings experience as a physician and scientist, expertise in health care faculty systems, biomedical research, clinical trial design, and patient safety, and a research-driven perspective on diabetes and obesity treatments from his work as a principal investigator.
Will there be a replacement director or any new compensation arrangements?
The filing does not name a successor or describe any new compensation arrangements. Investors should watch for a future 8-K or proxy disclosure if the Board appoints a new director or changes committee assignments.
04—Continue